The need for personalized therapy and companion diagnostics in prostate cancer
Author:
Affiliation:
1. Department of Pathology, University of Arizona College of Medicine, Arizona Cancer Center & the BIO5 Institute, Tucson, AZ 85724, USA.
Publisher
Future Medicine Ltd
Subject
Biochemistry, medical,Clinical Biochemistry,Drug Discovery
Link
https://www.futuremedicine.com/doi/pdf/10.2217/bmm.11.42
Reference13 articles.
1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
2. Molecular markers of prostate cancer
3. Complexities of Prostate-Cancer Risk
4. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Recent advances in the molecular targeted drugs for prostate cancer;International Urology and Nephrology;2023-01-31
2. Mapping genetic variability in mature miRNAs and miRNA binding sites in prostate cancer;Journal of Human Genetics;2021-06-08
3. Protein array-based companion diagnostics in precision medicine;Expert Review of Molecular Diagnostics;2020-12-01
4. Editorial Comment;Urology;2018-08
5. Conversion of bone marrow mesenchymal stem cells into type II alveolar epithelial cells reduces pulmonary fibrosis by decreasing oxidative stress in rats;Molecular Medicine Reports;2014-11-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3